

Step Therapy Requirements
Effective June 1, 2019

ANTIEMETICS STEP

Products Affected

Step 2:

- Sancuso 3.1 mg/24 hour transdermal patch
- Zuplenz 8 mg oral soluble film
- Zuplenz 4 mg oral soluble film

Details

Criteria	COVERAGE OF CERTAIN BRAND NAME ANTI-EMETIC MEDICATIONS REQUIRES A TRIAL OF BOTH GENERIC ONDANSETRON AND GENERIC GRANISETRON. IF THE REQUIRED DRUGS APPEAR IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED.
-----------------	--

ARB STEP

Products Affected

Step 2:

- Edarbi 40 mg tablet
- Edarbi 80 mg tablet
- Edarbyclor 40 mg-12.5 mg tablet
- Edarbyclor 40 mg-25 mg tablet

Details

Criteria	COVERAGE OF CERTAIN BRANDED ARBS AND ARB COMBOS REQUIRES A TRIAL OF TWO GENERIC ARB OR ARB COMBINATIONS. IF THE REQUIRED DRUGS APPEAR IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED.
-----------------	--

BRAND HMG STEP

Products Affected

Step 2:

- Altprev 20 mg tablet,extended release
- Altprev 40 mg tablet,extended release
- Altprev 60 mg tablet,extended release

Details

Criteria	COVERAGE OF BRAND NAME STATINS (HMGS) REQUIRES A TRIAL OF TWO GENERIC STATIN MEDICATIONS. IF THE REQUIRED DRUGS APPEAR IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED.
-----------------	---

BRAND TOPICAL ANTIFUNGALS STEP

Products Affected

Step 2:

- Ertaczo 2 % topical cream
- Exelderm 1 % topical cream
- Exelderm 1 % topical solution
- luliconazole 1 % topical cream
- Luzu 1 % topical cream
- Mentax 1 % topical cream
- Naftin 1 % topical gel
- Naftin 2 % topical gel
- Oxistat 1 % lotion

Details

Criteria	COVERAGE OF BRAND NAME TOPICAL ANTIFUNGALS REQUIRES A TRIAL OF TWO GENERIC TOPICAL ANTIFUNGAL MEDICATIONS. IF THE REQUIRED DRUGS APPEAR IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED.
-----------------	--

BRAND TOPICAL STEROIDS STEP

Products Affected

Step 2:

- Capex 0.01 % shampoo
- Cordran Tape Large Roll 4 mcg/cm²
- Desonate 0.05 % topical gel
- Enstilar 0.005 %-0.064 % topical foam
- halobetasol propionate 0.05 % topical foam
- Halog 0.1 % topical cream
- Halog 0.1 % topical ointment
- Impoyz 0.025 % topical cream
- Pandel 0.1 % topical cream
- Taclonex 0.005 %-0.064 % topical suspension
- Topicort 0.25 % topical spray

Details

Criteria	COVERAGE OF BRAND NAME TOPICAL STEROIDS REQUIRES A TRIAL OF TWO DIFFERENT GENERIC TOPICAL STEROID MEDICATIONS. IF TWO DIFFERENT GENERIC TOPICAL STEROID MEDICATIONS ARE NOT AVAILABLE TO TREAT A SPECIFIC DIAGNOSIS, THEN A TRIAL OF ONE GENERIC TOPICAL STEROID MEDICATION SATISFIES THIS REQUIREMENT. IF THE REQUIRED DRUGS APPEAR IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED.
-----------------	---

CUPRIMINE

Products Affected

Step 2:

- Cuprimine 250 mg capsule

Details

Criteria	COVERAGE OF CUPRIMINE REQUIRES A TRIAL OF DEPEN. IF THE REQUIRED DRUG APPEARS IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED.
-----------------	--

INVEGA

Products Affected

Step 2:

- Invega Sustenna 117 mg/0.75 mL intramuscular syringe
- Invega Sustenna 156 mg/mL intramuscular syringe
- Invega Sustenna 234 mg/1.5 mL intramuscular syringe
- Invega Sustenna 39 mg/0.25 mL intramuscular syringe
- Invega Sustenna 78 mg/0.5 mL intramuscular syringe
- Invega Trinza 273 mg/0.875 mL intramuscular syringe
- Invega Trinza 410 mg/1.315 mL intramuscular syringe
- Invega Trinza 546 mg/1.75 mL intramuscular syringe
- Invega Trinza 819 mg/2.625 mL intramuscular syringe

Details

Criteria	COVERAGE OF INVEGA REQUIRES A TRIAL OF RISPERIDONE AND AT LEAST ONE OTHER ANTIPSYCHOTIC MEDICATION OR MOOD STABILIZER. IF THE REQUIRED DRUGS APPEAR IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED.
-----------------	--

SAVELLA STEP

Products Affected

Step 2:

- Savella 100 mg tablet
- Savella 12.5 mg (5)-25 mg(8)-50mg(42) tablets in a dose pack
- Savella 12.5 mg tablet
- Savella 25 mg tablet
- Savella 50 mg tablet

Details

Criteria	COVERAGE OF SAVELLA REQUIRES A TRIAL OF DULOXETINE. IF THE REQUIRED DRUG APPEARS IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED.
-----------------	---

SOOLANTRA

Products Affected

Step 2:

- Soolantra 1 % topical cream

Details

Criteria	COVERAGE OF SOOLANTRA REQUIRES A TRIAL OF ONE GENERIC TOPICAL METRONIDAZOLE PRODUCT. IF THE REQUIRED DRUG APPEARS IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED.
-----------------	--

TRELEGY ELLIPTA STEP

Products Affected

Step 2:

- Trelegy Ellipta 100 mcg-62.5 mcg-25 mcg powder for inhalation

Details

Criteria	COVERAGE OF TRELEGY ELLIPTA REQUIRES A TRIAL OF ONE PREFERRED LONG-ACTING MUSCARINIC RECEPTOR ANTAGONIST (LAMA) OR ONE PREFERRED LONG-ACTING MUSCARINIC RECEPTOR ANTAGONIST/LONG-ACTING BETA AGONIST (LAMA/LABA) OR ONE PREFERRED LONG-ACTING BETA AGONIST/INHALED CORTICOSTEROID (LABA/ICS). IF A REQUIRED DRUG APPEARS IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED.
-----------------	---

TRIENTINE STEP

Products Affected

Step 2:

- trientine 250 mg capsule

Details

Criteria	COVERAGE OF TRIENTINE REQUIRES A TRIAL OF DEPEN. IF THE REQUIRED DRUG APPEARS IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED.
-----------------	--

TRIPTAN INJECTABLE STEP

Products Affected

Step 2:

- Zembrace Symtouch 3 mg/0.5 mL subcutaneous pen injector

Details

Criteria	COVERAGE OF CERTAIN BRAND NAME INJECTABLE TRIPTAN MEDICATIONS REQUIRES A TRIAL OF A GENERIC SUMATRIPTAN INJECTABLE. IF THE REQUIRED DRUG APPEARS IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED.
-----------------	---

TRIPTAN STEP

Products Affected

Step 2:

- Onzetra Xsail 11 mg powder for nasal inhalation
- Treximet 10 mg-60 mg tablet

Details

Criteria	COVERAGE OF CERTAIN BRAND NAME TRIPTAN MEDICATIONS REQUIRES A TRIAL OF TWO GENERIC TRIPTAN MEDICATIONS. IF THE REQUIRED DRUGS APPEAR IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED.
-----------------	---

ULORIC STEP

Products Affected

Step 2:

- Uloric 40 mg tablet
- Uloric 80 mg tablet

Details

Criteria	COVERAGE OF ULORIC REQUIRES A TRIAL OF GENERIC ALLOPURINOL. IF THE REQUIRED DRUG APPEARS IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED.
-----------------	---

ZELAPAR STEP

Products Affected

Step 2:

- Zelapar 1.25 mg disintegrating tablet

Details

Criteria	COVERAGE OF ZELAPAR REQUIRES A TRIAL OF ORAL SELEGILINE. IF THE REQUIRED DRUG APPEARS IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED.
-----------------	--

ZYFLO, ZILEUTON ER STEP

Products Affected

Step 2:

- zileuton ER 600 mg tablet, extended release 12hr mphase
- Zyflo 600 mg tablet

Details

Criteria	COVERAGE OF ZYFLO OR ZILEUTON ER REQUIRES TRIALS OF BOTH ORAL MONTELUKAST AND ZAFIRLUKAST. IF THE REQUIRED DRUGS APPEAR IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED.
-----------------	--

Index

A

Altoprev 20 mg tablet,extended release..... 3
Altoprev 40 mg tablet,extended release..... 3
Altoprev 60 mg tablet,extended release..... 3

C

Capex 0.01 % shampoo..... 5
Cordran Tape Large Roll 4 mcg/cm² 5
Cuprimine 250 mg capsule 6

D

Desonate 0.05 % topical gel..... 5

E

Edarbi 40 mg tablet..... 2
Edarbi 80 mg tablet..... 2
Edarbyclor 40 mg-12.5 mg tablet 2
Edarbyclor 40 mg-25 mg tablet 2
Enstilar 0.005 %-0.064 % topical foam 5
Ertaczo 2 % topical cream 4
Exelderm 1 % topical cream..... 4
Exelderm 1 % topical solution..... 4

H

halobetasol propionate 0.05 % topical foam5
Halog 0.1 % topical cream..... 5
Halog 0.1 % topical ointment 5

I

Impoyz 0.025 % topical cream 5
Invega Sustenna 117 mg/0.75 mL
intramuscular syringe..... 7
Invega Sustenna 156 mg/mL intramuscular
syringe..... 7
Invega Sustenna 234 mg/1.5 mL
intramuscular syringe..... 7
Invega Sustenna 39 mg/0.25 mL
intramuscular syringe..... 7
Invega Sustenna 78 mg/0.5 mL
intramuscular syringe..... 7
Invega Trinza 273 mg/0.875 mL
intramuscular syringe..... 7
Invega Trinza 410 mg/1.315 mL
intramuscular syringe..... 7
Invega Trinza 546 mg/1.75 mL
intramuscular syringe..... 7
Invega Trinza 819 mg/2.625 mL
intramuscular syringe..... 7

L

luliconazole 1 % topical cream 4
Luzu 1 % topical cream 4

M

Mentax 1 % topical cream 4

N

Naftin 1 % topical gel 4
Naftin 2 % topical gel 4

O

Onzetra Xsail 11 mg powder for nasal
inhalation..... 13
Oxistat 1 % lotion 4

P

Pandel 0.1 % topical cream..... 5

S

Sancuso 3.1 mg/24 hour transdermal patch 1
Savella 100 mg tablet..... 8
Savella 12.5 mg (5)-25 mg(8)-50mg(42)
tablets in a dose pack 8
Savella 12.5 mg tablet..... 8
Savella 25 mg tablet..... 8
Savella 50 mg tablet..... 8
Soolantra 1 % topical cream 9

T

Taclonex 0.005 %-0.064 % topical
suspension..... 5
Topicort 0.25 % topical spray..... 5
Trelegy Ellipta 100 mcg-62.5 mcg-25 mcg
powder for inhalation..... 10
Treximet 10 mg-60 mg tablet 13
trientine 250 mg capsule 11

U

Uloric 40 mg tablet 14
Uloric 80 mg tablet 14

Z

Zelapar 1.25 mg disintegrating tablet 15
Zembrace Syntouch 3 mg/0.5 mL
subcutaneous pen injector 12
zileuton ER 600 mg tablet,extended release
12hr mphase 16
Zuplenz 4 mg oral soluble film..... 1
Zuplenz 8 mg oral soluble film..... 1
Zyflo 600 mg tablet..... 16